Last reviewed · How we verify
CAR-T CD19
Chimeric antigen receptor T-cell therapy targeting CD19
Chimeric antigen receptor T-cell therapy targeting CD19 Used for Relapsed or refractory B-cell lymphomas.
At a glance
| Generic name | CAR-T CD19 |
|---|---|
| Sponsor | Sheba Medical Center |
| Drug class | CAR-T cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CAR-T cells are genetically modified to express a chimeric antigen receptor that recognizes and binds to CD19 on the surface of B cells, leading to their destruction.
Approved indications
- Relapsed or refractory B-cell lymphomas
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
Key clinical trials
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (PHASE2, PHASE3)
- Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation (PHASE2)
- Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation (PHASE1)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Co-administration of CART22-65s and huCART19 for B-ALL (PHASE1, PHASE2)
- CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (PHASE2)
- MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAR-T CD19 CI brief — competitive landscape report
- CAR-T CD19 updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI